Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1701963 Monotherapy and in Combination With Trametinib in KRAS Mutated Solid Tumours
NCT04111458Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2019
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of BI 1701963 in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Dose-Limiting Toxicities at 3 years and 1 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
BI 1701963
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04111458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111458.